RegenETP Management
Management criteria checks 4/4
RegenETP's CEO is Richard Hague, appointed in Apr 2020, has a tenure of 3.67 years. total yearly compensation is $479.81K, comprised of 93.5% salary and 6.5% bonuses, including company stock and options. directly owns 0.62% of the company’s shares, worth €1.01K. The average tenure of the management team and the board of directors is 4.5 years and 6.5 years respectively.
Key information
Richard Hague
Chief executive officer
US$479.8k
Total compensation
| CEO salary percentage | 93.5% |
| CEO tenure | 3.7yrs |
| CEO ownership | 0.6% |
| Management average tenure | 4.5yrs |
| Board average tenure | 6.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$8m |
| Dec 31 2022 | US$480k | US$449k | -US$8m |
| Sep 30 2022 | n/a | n/a | -US$16m |
| Jun 30 2022 | n/a | n/a | -US$13m |
| Mar 31 2022 | n/a | n/a | -US$17m |
| Dec 31 2021 | US$1m | US$359k | -US$30m |
| Sep 30 2021 | n/a | n/a | -US$32m |
| Jun 30 2021 | n/a | n/a | -US$38m |
| Mar 31 2021 | n/a | n/a | -US$47m |
| Dec 31 2020 | US$996k | US$358k | -US$43m |
| Sep 30 2020 | n/a | n/a | -US$54m |
| Jun 30 2020 | n/a | n/a | -US$70m |
| Mar 31 2020 | n/a | n/a | -US$80m |
| Dec 31 2019 | US$2m | US$273k | -US$92m |
Compensation vs Market: Richard's total compensation ($USD479.81K) is about average for companies of similar size in the German market ($USD418.12K).
Compensation vs Earnings: Richard's compensation has been consistent with company performance over the past year.
CEO
Richard Hague (63 yo)
3.7yrs
Tenure
US$479,808
Compensation
Mr. Richard Hague is Director of Remedium Bio, Inc since 2022. He serves as President at PolarityTE, Inc. since August 2019 and its Chief Executive Officer since August 2021 and also served as its Chief Op...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.7yrs | US$479.81k | 0.62% € 1.0k | |
| Chief Scientific Officer and VP of R&D | 5.4yrs | no data | no data | |
| Vice President of Investor Relations & Strategy | 5.6yrs | no data | no data | |
| Chief Legal Officer | no data | no data | no data | |
| Vice President of Marketing & Public Relations | no data | no data | no data | |
| Vice President of Sales | 5.4yrs | no data | no data | |
| Senior VP of Corporate Development & President of Contract Services | no data | no data | no data | |
| Chief Medical Officer | 2.3yrs | no data | no data | |
| Senior Vice President of Manufacturing Operations | 1.1yrs | no data | no data |
4.5yrs
Average Tenure
Experienced Management: NJT's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$479.81k | 0.62% € 1.0k | |
| Member of Clinical Advisory board | no data | no data | no data | |
| Member of Clinical Advisory Board | 7yrs | no data | no data | |
| Member of Clinical Advisory Board | 7yrs | no data | no data | |
| Member of Clinical Advisory Board | 7yrs | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | 6.5yrs | no data | no data | |
| Member of Clinical Advisory Board | 6.5yrs | no data | no data | |
| Member of Clinical Advisory Board | 6.5yrs | no data | no data |
6.5yrs
Average Tenure
Experienced Board: NJT's board of directors are considered experienced (6.5 years average tenure).